{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:46:00Z","timestamp":1791841560260,"version":"4.3.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Landmand af \u00d8lufg\u00e5rd Peder Nielsen Kristensen\u2019s Memorial Fund"},{"name":"The Danish health authorities","award":["4-1612-391\/1"],"award-info":[{"award-number":["4-1612-391\/1"]}]},{"DOI":"10.13039\/100019180","name":"HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["101041231"],"award-info":[{"award-number":["101041231"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","award":["101057438"],"award-info":[{"award-number":["101057438"]}],"id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck Foundation","doi-asserted-by":"publisher","award":["R238-2016-3349"],"award-info":[{"award-number":["R238-2016-3349"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF19OC0058238"],"award-info":[{"award-number":["NNF19OC0058238"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","award":["8056-00010B"],"award-info":[{"award-number":["8056-00010B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002808","name":"Carlsbergfondet","doi-asserted-by":"publisher","award":["CF20-0424"],"award-info":[{"award-number":["CF20-0424"]}],"id":[{"id":"10.13039\/501100002808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009512","name":"Agnes og Poul Friis Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009512","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Slagtermester Max W\u00f8rzner og Hustru Inger W\u00f8rzners Mindelegat"},{"DOI":"10.13039\/501100005747","name":"A.P. M\u00f8ller og Hustru Chastine Mc-Kinney M\u00f8llers Fond til almene Formaal","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006309","name":"Riisfort Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006309","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-026-01718-7","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:15:49Z","timestamp":1784870149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRISPR integration of an FLT3 CAR into the TRAC locus generates CAR T cells for AML"],"prefix":"10.1186","volume":"18","author":[{"given":"Maya G.","family":"Noer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7255-3139","authenticated-orcid":false,"given":"Kimmie B.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanna S.","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrid Fu","family":"Skjelbostad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik H.","family":"Rothemejer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wittenborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Famm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6968-148X","authenticated-orcid":false,"given":"Torben","family":"Barington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin K.","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5892-1174","authenticated-orcid":false,"given":"Mike B.","family":"Barnkob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne K.","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-0297","authenticated-orcid":false,"given":"Rasmus O.","family":"Bak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"22","key":"1718_CR1","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"12","key":"1718_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, G\u00f6nen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079\u201389.","journal-title":"N Engl J Med"},{"issue":"23","key":"1718_CR3","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"1718_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108(2):353\u201366.","journal-title":"Haematologica"},{"issue":"4","key":"1718_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","volume":"10","author":"NJ Short","year":"2020","unstructured":"Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10(4):506\u201325.","journal-title":"Cancer Discov"},{"issue":"22","key":"1718_CR6","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/blood.2020007626","volume":"137","author":"LK Schmalbrock","year":"2021","unstructured":"Schmalbrock LK, Dolnik A, Cocciardi S, Str\u00e4ng E, Theis F, Jahn N, et al. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021;137(22):3093\u2013104.","journal-title":"Blood"},{"issue":"8","key":"1718_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","volume":"9","author":"CM McMahon","year":"2019","unstructured":"McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia. Cancer Discov. 2019;9(8):1050\u201363.","journal-title":"Cancer Discov"},{"issue":"7","key":"1718_CR8","doi-asserted-by":"publisher","first-page":"7844","DOI":"10.1002\/cam4.5551","volume":"12","author":"S Abbasi","year":"2023","unstructured":"Abbasi S, Totmaj MA, Abbasi M, Hajazimian S, Goleij P, Behroozi J, et al. Chimeric antigen receptor T (CAR-T) cells: novel cell therapy for hematological malignancies. Cancer Med. 2023;12(7):7844\u201358.","journal-title":"Cancer Med"},{"issue":"6","key":"1718_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1718_CR10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","volume":"25","author":"DT MacLeod","year":"2017","unstructured":"MacLeod DT, Antony J, Martin AJ, Moser RJ, Hekele A, Wetzel KJ, et al. Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells. Mol Ther. 2017;25(4):949\u201361.","journal-title":"Mol Ther"},{"key":"1718_CR11","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.944204","volume":"30","author":"DV Parums","year":"2024","unstructured":"Parums DV. Editorial: first regulatory approvals for CRISPR-Cas9 therapeutic gene editing for sickle cell disease and transfusion-dependent \u03b2-thalassemia. Med Sci Monit. 2024;30:e944204.","journal-title":"Med Sci Monit"},{"issue":"7643","key":"1718_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113\u20137.","journal-title":"Nature"},{"issue":"7","key":"1718_CR13","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","volume":"14","author":"SK Pal","year":"2024","unstructured":"Pal SK, Tran B, Haanen J, Hurwitz ME, Sacher A, Tannir NM, et al. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov. 2024;14(7):1176\u201389.","journal-title":"Cancer Discov"},{"issue":"1","key":"1718_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S1470-2045(24)00508-4","volume":"26","author":"SP Iyer","year":"2025","unstructured":"Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, et al. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol. 2025;26(1):110\u201322.","journal-title":"Lancet Oncol"},{"key":"1718_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03899-x","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Wang H, Wu X, He C, Lin S, et al. Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03899-x.","journal-title":"Nat Med"},{"issue":"10","key":"1718_CR16","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa R, Georgiadis C, Syed F, Zhan H, Etuk A, Gkazi SA, et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N Engl J Med. 2023;389(10):899\u2013910.","journal-title":"N Engl J Med"},{"issue":"2","key":"1718_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody S, Matous JV, Chhabra S, Liedtke M, Sidana S, Oluwole OO, et al. Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29(2):422\u20139.","journal-title":"Nat Med"},{"issue":"18","key":"1718_CR18","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(18):4890-904 e9.","journal-title":"Cell"},{"issue":"14","key":"1718_CR19","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/JCO-24-01933","volume":"43","author":"FL Locke","year":"2025","unstructured":"Locke FL, Munoz JL, Tees MT, Lekakis LJ, de Vos S, Nath R, et al. Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel\/ALLO-501 in relapsed\/refractory large B-cell lymphoma: phase I experience from the ALPHA2\/ALPHA clinical studies. J Clin Oncol. 2025;43(14):1695\u2013705.","journal-title":"J Clin Oncol"},{"key":"1718_CR20","doi-asserted-by":"crossref","unstructured":"Pedersen MG, Moller BK, Bak RO. Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML. Biomedicines. 2022;10(10):2441.","DOI":"10.3390\/biomedicines10102441"},{"issue":"10","key":"1718_CR21","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.ymthe.2020.06.022","volume":"28","author":"C Sommer","year":"2020","unstructured":"Sommer C, Cheng HY, Nguyen D, Dettling D, Yeung YA, Sutton J, et al. Allogeneic FLT3 CAR T cells with an off-switch exhibit potent activity against AML and can be depleted to expedite bone marrow recovery. Mol Ther. 2020;28(10):2237\u201351.","journal-title":"Mol Ther"},{"issue":"3","key":"1718_CR22","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3324\/haematol.2019.233882","volume":"106","author":"V Wiebking","year":"2021","unstructured":"Wiebking V, Lee CM, Mostrel N, Lahiri P, Bak R, Bao G, et al. Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing alphabeta T cell-depleted haploidentical hematopoietic stem cell transplantation. Haematologica. 2021;106(3):847\u201358.","journal-title":"Haematologica"},{"issue":"7","key":"1718_CR23","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"JN Kochenderfer","year":"2009","unstructured":"Kochenderfer JN, Feldman SA, Zhao Y, Xu H, Black MA, Morgan RA, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009;32(7):689\u2013702.","journal-title":"J Immunother"},{"issue":"2","key":"1718_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nprot.2017.143","volume":"13","author":"RO Bak","year":"2018","unstructured":"Bak RO, Dever DP, Porteus MH. CRISPR\/Cas9 genome editing in human hematopoietic stem cells. Nat Protoc. 2018;13(2):358\u201376.","journal-title":"Nat Protoc"},{"issue":"4","key":"1718_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/hgtb.2019.031","volume":"30","author":"B Furuta-Hanawa","year":"2019","unstructured":"Furuta-Hanawa B, Yamaguchi T, Uchida E. Two-dimensional droplet digital PCR as a tool for titration and integrity evaluation of recombinant adeno-associated viral vectors. Hum Gene Ther Methods. 2019;30(4):127\u201336.","journal-title":"Hum Gene Ther Methods"},{"issue":"3","key":"1718_CR26","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/mt.2015.197","volume":"24","author":"MJ Osborn","year":"2016","unstructured":"Osborn MJ, Webber BR, Knipping F, Lonetree CL, Tennis N, DeFeo AP, et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR\/Cas9, and megaTAL nucleases. Mol Ther. 2016;24(3):570\u201381.","journal-title":"Mol Ther"},{"key":"1718_CR27","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.27873","author":"RO Bak","year":"2017","unstructured":"Bak RO, Dever DP, Reinisch A, Cruz Hernandez D, Majeti R, Porteus MH. Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR\/Cas9 and AAV6. Elife. 2017. https:\/\/doi.org\/10.7554\/eLife.27873.","journal-title":"Elife"},{"key":"1718_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-1-4939-9170-9_9","volume":"1961","author":"A Laustsen","year":"2019","unstructured":"Laustsen A, Bak RO. Electroporation-based CRISPR\/Cas9 gene editing using Cas9 protein and chemically modified sgRNAs. Methods Mol Biol. 2019;1961:127\u201334.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"1718_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06524-0","volume":"23","author":"L Dan","year":"2025","unstructured":"Dan L, Kang-Zheng L. Optimizing viral transduction in immune cell therapy manufacturing: key process design considerations. J Transl Med. 2025;23(1):501.","journal-title":"J Transl Med"},{"issue":"12","key":"1718_CR30","doi-asserted-by":"publisher","first-page":"6082","DOI":"10.1016\/j.ymthe.2025.08.032","volume":"33","author":"NS Mikkelsen","year":"2025","unstructured":"Mikkelsen NS, Ravendran S, Brokso AD, Skjelbostad SF, Pedersen MG, Fang H, et al. Orthogonal CRISPR systems for targeted integration and multiplex base editing enable nonviral engineering of allogeneic CAR-T cells. Mol Ther. 2025;33(12):6082\u2013100. https:\/\/doi.org\/10.1016\/j.ymthe.2025.08.032.","journal-title":"Mol Ther"},{"issue":"1","key":"1718_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41467-023-43413-w","volume":"15","author":"R Baik","year":"2024","unstructured":"Baik R, Cromer MK, Glenn SE, Vakulskas CA, Chmielewski KO, Dudek AM, et al. Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells. Nat Commun. 2024;15(1):111.","journal-title":"Nat Commun"},{"issue":"1","key":"1718_CR32","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.1038\/s41467-025-61696-z","volume":"16","author":"H Chen","year":"2025","unstructured":"Chen H, Tan Q, Li L, Li L, Fu J, Zhu W, et al. Refined DNA repair manipulation enables a universal knock-in strategy in mouse embryos. Nat Commun. 2025;16(1):6502.","journal-title":"Nat Commun"},{"issue":"2","key":"1718_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1056\/NEJMoa2505478","volume":"394","author":"R Chiesa","year":"2026","unstructured":"Chiesa R, Georgiadis C, Rashed H, Preece R, Hardefeldt P, Chu J, et al. Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia. N Engl J Med. 2026;394(2):152\u201365.","journal-title":"N Engl J Med"},{"issue":"16","key":"1718_CR34","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. N Engl J Med. 2024;390(16):1467\u201380.","journal-title":"N Engl J Med"},{"key":"1718_CR35","doi-asserted-by":"crossref","unstructured":"Li Z, Zheng Q, Yang K, Xu T, Wang L, Wang X, et al. CD7 CART Therapy Bridging Allo-HSCT Remarkably Improves Long-Term DFS in Refractory\/Relapsed T-ALL\/LBL. Transplant Cell Ther. 2025;31(2):73 e1- e11.","DOI":"10.1016\/j.jtct.2024.11.009"},{"issue":"10","key":"1718_CR36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024861","volume":"145","author":"P Lu","year":"2025","unstructured":"Lu P, Zhang X, Yang J, Li J, Qiu L, Gong M, et al. Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia. Blood. 2025;145(10):1022\u201333.","journal-title":"Blood"},{"key":"1718_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003882","author":"NK Mehta","year":"2022","unstructured":"Mehta NK, Pfluegler M, Meetze K, Li B, Sindel I, Vogt F, et al. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-003882.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1718_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40364-023-00501-9","volume":"11","author":"R Shao","year":"2023","unstructured":"Shao R, Li Z, Xin H, Jiang S, Zhu Y, Liu J, et al. Biomarkers as targets for CAR-T\/NK cell therapy in AML. Biomark Res. 2023;11(1):65.","journal-title":"Biomark Res"},{"issue":"6","key":"1718_CR39","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/j.ymthe.2025.03.052","volume":"33","author":"M Khalifeh","year":"2025","unstructured":"Khalifeh M, Hopewell E, Salman H. CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes. Mol Ther. 2025;33(6):2441\u201353.","journal-title":"Mol Ther"},{"issue":"9","key":"1718_CR40","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-19-1093","volume":"19","author":"B Brauchle","year":"2020","unstructured":"Brauchle B, Goldstein RL, Karbowski CM, Henn A, Li CM, B\u00fccklein VL, et al. Characterization of a novel FLT3 BiTE molecule for the treatment of acute myeloid leukemia. Mol Cancer Ther. 2020;19(9):1875\u201388.","journal-title":"Mol Cancer Ther"},{"key":"1718_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000845","author":"ML Baroni","year":"2020","unstructured":"Baroni ML, Sanchez Martinez D, Gutierrez Aguera F, Roca Ho H, Castella M, Zanetti SR, et al. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000845.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1718_CR42","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger A, Kramer M, R\u00f6llig C, Thiede C, Bornh\u00e4user M, von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4(6):e218.","journal-title":"Blood Cancer J"},{"issue":"8","key":"1718_CR43","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/leu.2017.147","volume":"31","author":"L Chen","year":"2017","unstructured":"Chen L, Mao H, Zhang J, Chu J, Devine S, Caligiuri MA, et al. Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Leukemia. 2017;31(8):1830\u20134.","journal-title":"Leukemia"},{"issue":"1","key":"1718_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0603-7","volume":"11","author":"Y Wang","year":"2018","unstructured":"Wang Y, Xu Y, Li S, Liu J, Xing Y, Xing H, et al. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells. J Hematol Oncol. 2018;11(1):60.","journal-title":"J Hematol Oncol"},{"issue":"7978","key":"1718_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","volume":"621","author":"G Casirati","year":"2023","unstructured":"Casirati G, Cosentino A, Mucci A, Salah Mahmoud M, Ugarte Zabala I, Zeng J, et al. Epitope editing enables targeted immunotherapy of acute myeloid leukaemia. Nature. 2023;621(7978):404\u201314.","journal-title":"Nature"},{"issue":"1","key":"1718_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01143-2","volume":"14","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Borthakur G, Daver N, DiNardo CD, Issa G, Jabbour E, et al. Current status and research directions in acute myeloid leukemia. Blood Cancer J. 2024;14(1):163.","journal-title":"Blood Cancer J"},{"issue":"9","key":"1718_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s00894-022-05254-0","volume":"28","author":"S Zhou","year":"2022","unstructured":"Zhou S, Yang B, Xu Y, Gu A, Peng J, Fu J. Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy. J Mol Model. 2022;28(9):247.","journal-title":"J Mol Model"},{"issue":"7","key":"1718_CR48","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","volume":"6","author":"CC Smith","year":"2022","unstructured":"Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144\u201355.","journal-title":"Blood Adv"},{"issue":"2","key":"1718_CR49","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3324\/haematol.2022.281456","volume":"108","author":"LM Niswander","year":"2023","unstructured":"Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, et al. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia. Haematologica. 2023;108(2):457\u201371.","journal-title":"Haematologica"},{"issue":"1","key":"1718_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.200944","volume":"33","author":"QR Bubb","year":"2025","unstructured":"Bubb QR, Balood M, Seir GE, Swartzrock L, Haslett E, Ho K, et al. Development of multivalent CAR T cells as dual immunotherapy and conditioning agents. Mol Ther Oncol. 2025;33(1):200944.","journal-title":"Mol Ther Oncol"},{"key":"1718_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2023.100751","volume":"31","author":"JC Boucher","year":"2023","unstructured":"Boucher JC, Shrestha B, Vishwasrao P, Leick M, Cervantes EV, Ghafoor T, et al. Bispecific CD33\/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Ther Oncolytics. 2023;31:100751.","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"1718_CR52","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00262-022-03303-4","volume":"72","author":"M Suematsu","year":"2023","unstructured":"Suematsu M, Yagyu S, Yoshida H, Osone S, Nakazawa Y, Sugita K, et al. Targeting FLT3-specific chimeric antigen receptor T cells for acute lymphoblastic leukemia with KMT2A rearrangement. Cancer Immunol Immunother. 2023;72(4):957\u201368.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"1718_CR53","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","volume":"31","author":"JK Jadlowsky","year":"2025","unstructured":"Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med. 2025;31(4):1134\u201344.","journal-title":"Nat Med"},{"issue":"3","key":"1718_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102636","volume":"36","author":"N Kalter","year":"2025","unstructured":"Kalter N, Fuster-Garcia C, Silva A, Ronco-Diaz V, Roncelli S, Turchiano G, et al. Off-target effects in CRISPR-Cas genome editing for human therapeutics: progress and challenges. Mol Ther Nucleic Acids. 2025;36(3):102636.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"21","key":"1718_CR55","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","volume":"186","author":"CA Tsuchida","year":"2023","unstructured":"Tsuchida CA, Brandes N, Bueno R, Trinidad M, Mazumder T, Yu B, et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell. 2023;186(21):4567-82 e20.","journal-title":"Cell"},{"issue":"8","key":"1718_CR56","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas CA, Dever DP, Rettig GR, Turk R, Jacobi AM, Collingwood MA, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med. 2018;24(8):1216\u201324.","journal-title":"Nat Med"},{"issue":"8","key":"1718_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100677","volume":"6","author":"YR Li","year":"2025","unstructured":"Li YR, Zhu Y, Fang Y, Lyu Z, Yang L. Emerging trends in clinical allogeneic CAR cell therapy. Med. 2025;6(8):100677.","journal-title":"Med"},{"issue":"7787","key":"1718_CR58","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei J, Long L, Zheng W, Dhungana Y, Lim SA, Guy C, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. 2019;576(7787):471\u20136.","journal-title":"Nature"},{"issue":"1","key":"1718_CR59","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","volume":"7","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer. 2019;7(1):304.","journal-title":"J Immunother Cancer"},{"key":"1718_CR60","doi-asserted-by":"crossref","unstructured":"Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, et al. TGF-beta inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5(4):e133977.","DOI":"10.1172\/jci.insight.133977"},{"issue":"10","key":"1718_CR61","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/eji.202049107","volume":"51","author":"Y Guo","year":"2021","unstructured":"Guo Y, Xu B, Wu Z, Bo J, Tong C, Chen D, et al. Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T cells from allogeneic NK cell-mediated lysis. Eur J Immunol. 2021;51(10):2513\u201321.","journal-title":"Eur J Immunol"},{"issue":"6","key":"1718_CR62","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.ymthe.2024.11.035","volume":"33","author":"YR Li","year":"2025","unstructured":"Li YR, Fang Y, Niu S, Chen Y, Lyu Z, Yang L. Managing allorejection in off-the-shelf CAR-engineered cell therapies. Mol Ther. 2025;33(6):2368\u201390.","journal-title":"Mol Ther"},{"key":"1718_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020. https:\/\/doi.org\/10.1126\/science.aba7365.","journal-title":"Science"},{"issue":"1","key":"1718_CR64","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13059-023-02928-7","volume":"24","author":"V Glaser","year":"2023","unstructured":"Glaser V, Flugel C, Kath J, Du W, Drosdek V, Franke C, et al. Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells. Genome Biol. 2023;24(1):89.","journal-title":"Genome Biol"},{"key":"1718_CR66","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.omtm.2022.03.018","volume":"25","author":"J Kath","year":"2022","unstructured":"Kath J, Du W, Pruene A, Braun T, Thommandru B, Turk R, et al. Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells. Mol Ther Methods Clin Dev. 2022;25:311\u201330.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"1718_CR67","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12943-023-01799-7","volume":"22","author":"H Balke-Want","year":"2023","unstructured":"Balke-Want H, Keerthi V, Gkitsas N, Mancini AG, Kurgan GL, Fowler C, et al. Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing. Mol Cancer. 2023;22(1):100.","journal-title":"Mol Cancer"},{"key":"1718_CR68","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004446","author":"KP Mueller","year":"2022","unstructured":"Mueller KP, Piscopo NJ, Forsberg MH, Saraspe LA, Das A, Russell B, et al. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2021-004446.","journal-title":"J Immunother Cancer"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01718-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:02:03Z","timestamp":1791838923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01718-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1718"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01718-7","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PBMCs were obtained from healthy donors at the Blood Bank of Aarhus University Hospital. Buffy coats were provided as de-identified donor material, and no identifiable personal or clinical data were available to the researchers. According to Danish law, the use of anonymized buffy coats does not require specific ethical approval. All animal experiments were approved by the Danish Animal Experiments Inspectorate (approval 2023\u201315-0201\u201301407 and 2021\u201315-0201\u201300922).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ROB holds equity in Kamau Therapeutics and UNIKUM Therapeutics and is a cofounder of UNIKUM Therapeutics. Neither company was involved in the present study. ROB is an inventor on patents and patent applications related to CRISPR\/Cas and cellular therapies. ROB reports research funding from Novo Nordisk. The other authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"149"}}